(Q37212564)

English

Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae

scientific article published on 17 June 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

1 reference

Europe PubMed Central

Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Neisseria meningitidis

1 reference

based on heuristic

inferred from title

Streptococcus pneumoniae

1 reference

based on heuristic

inferred from title

Haemophilus influenzae

object named as

Haemophilus influenzae

1 reference

based on heuristic

inferred from title

object named as

Jodie McVernon

2

0 references

Caroline Trotter

object named as

Caroline L Trotter

1

0 references

David Goldblatt

object named as

David Goldblatt

6

0 references

Joachim Hombach

7

object named as

Joachim Hombach

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Cynthia G Whitney

4

object named as

Cynthia G Whitney

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

author name string

Mary E Ramsay

3

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

E Kim Mulholland

5

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Marie-Paule Kieny

8

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

SAGE subgroup

9

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

language of work or name

0 references

publication date

17 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

4434-4445

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Observations on the nasopharyngeal carriage of Haemophilus influenzae type b in children in Kampala, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

A population-based survey of Haemophilus influenzae type b nasopharyngeal carriage prevalence in Lombok Island, Indonesia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Decreased point prevalence of Haemophilus influenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with hib polyribosylribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in co

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Carriage of Haemophilus influenzae in healthy Gambian children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Mathematical models of Haemophilus influenzae type b.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Immunogenicity and reactogenicity to Haemophilus influenzae type B (Hib) conjugate vaccine among rural Alaska adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Manson Lecture. Meningococcal meningitis in Africa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

A review of vaccine research and development: meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

The changing face of meningococcal disease in West Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Neisseria meningitidis: an overview of the carriage state

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Meningococcal carriage in the African meningitis belt

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Antimicrobial resistance in developing countries. Part I: recent trends and current status

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Streptococcus pneumoniae colonisation: the key to pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

The potential indirect effect of conjugate pneumococcal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Serotype distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of Streptococcus pneumoniae among children in rural Mozambique

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Use of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in Pakistan for surveillance for antimicrobial resistance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Throat carriage of Streptococcus pneumoniae and Streptococcus pyogenes among infants and children in Zambia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Colonisation of Haemophilus influenzae and Streptococcus pneumoniae in the upper respiratory tract of neonates in Papua New Guinea: primary acquisition, duration of carriage, and relationship to carriage in mothers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Longitudinal study on pneumococcal carriage during the first year of life in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Combination conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Haemophilus influenzae type b vaccines: history, choice and comparisons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

The Meningitis Vaccine Project

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Progress in vaccination against Haemophilus influenzae type b in the Americas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197 conjugate vaccine in a large defined United States population: a four-year eight-month follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. The Israeli Pediatric Bacteremia and Meningitis Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Immunisation of infants in Iceland against Haemophilus influenzae type b

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Invasive disease due to Haemophilus influenzae type b during the first six years of general vaccination of Swedish children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Incidence of Haemophilus influenzae type b meningitis during 18 years of vaccine use: observational study using routine hospital data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Experience with the prevention of invasive Haemophilus influenzae type b disease by vaccination in Alaska: the impact of persistent oropharyngeal carriage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

The effectiveness of Haemophilus influenzae type b conjugate vaccines in a high risk population measured using immunization register data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Impact of haemophilus influenzae type b conjugate vaccine in South Africa and Argentina

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Estimation of vaccine effectiveness using the screening method.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

EstimatingHaemophilus influenzaeType b Vaccine Effectiveness in England and Wales by Use of the Screening Method

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Antibody to Haemophilus influenzae type b after routine and catch-up vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Return of Haemophilus influenzae type b infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Re-emergence of Haemophilus influenzae type b (Hib) disease in The Gambia following successful elimination with conjugate Hib vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effectiveness of meningococcal C conjugate vaccine in teenagers in England

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

A surveillance network for meningococcal disease in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Progress in the prevention of pneumococcal infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Infant Hib vaccination and herd immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

The impact of conjugate vaccine on carriage of Haemophilus influenzae type b

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

The natural history of meningococcal carriage and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effect of Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization among Immunized and Unimmunized Children in a Community‐Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Nasopharyngeal colonization with heptavalent pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae with prolonged vaccine dosing intervals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Declining invasive pneumococcal disease in the U.S. elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Herd immunity after pneumococcal conjugate vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Impact of a regional Hib vaccination programme in Italy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vac

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations i

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Antibody Responses to Nasopharyngeal Carriage ofStreptococcus pneumoniaein Adults: A Longitudinal Household Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Effect of Community‐Wide Conjugate Pneumococcal Vaccine Use in Infancy on Nasopharyngeal Carriage through 3 Years of Age: A Cross‐Sectional Study in a High‐Risk Population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Nasopharyngeal colonization: a target for pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Could a single dose of pneumococcal conjugate vaccine in children be effective?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

Pneumococci in nasopharyngeal samples from Filipino children with acute respiratory infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

based on heuristic

inferred from DOI database lookup

Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.073

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.05.073

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37212564&oldid=2147127871"